Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
Artificial intelligence has undoubtedly been the hottest investing topic on Wall Street this year. And while it's hard to decide on a runner-up, weight-loss medicines deserve a spot high up on that list. Led by such products as Wegovy, manufactured by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), the area of obesity care is garnering substantial attention.
However, that alone doesn't make Novo Nordisk a buy, even as it leads this budding market. Can the drugmaker match the lofty expectations the market has for it? And can it do so over the long run? Let's find out.
One of Novo Nordisk's strengths is its focus on diabetes and obesity care. The company has been the leader in this field for a while. Novo Nordisk has a team of scientists and researchers that has, time and time again, successfully developed newer and better products.
Source Fool.com
